Sava Technologies today announced the appointment of John Bernard as its new chief commercial officer (CCO). London-based Sava, which develops a minimally invasive molecular sensing platform for continuous glucose monitoring (CGM), says the appointment marks a “decisive step” in its transition from clinical and technical progress to commercial execution. The company designed its multi-molecule biosensor […]
Sava Technologies
Sava Technologies reports first clinical evidence for CGM biosensor
Sava Technologies today announced the first 10-day clinical evidence for its microsensor-based continuous glucose monitor (CGM). London-based Sava completed an independent clinical study of 46 participants with type 1 and insulin-dependent type 2 diabetes. The study took place across sites in Oxford and Cambridge, UK. It demonstrated reliable glucose measurement using Sava’s proprietary microsensor technology […]
Sava raises $19M to advance glucose biosensor
Sava Technologies announced today that it raised $19 million in a Series A financing round to support its wearable biosensor technology. Balderton Capital and Pentland Ventures led the round, with new investors Norrsken VC and JamJar Investments joining, too. Other investors included True, Italian Founders Fund, Athletico Ventures, SOLO Investments and Exceptional Ventures. The funding […]
